LMR Partners’s VYNE Therapeutics VYNE Stock Holding History

LMR Partners’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,098	Closed	-$27K	–	1288
2021 Q3	$27K	Hold	1,098	–	–	﹤0.01%	971
2021 Q2	$69K	Buy	+1,098	New	+$86.9K	﹤0.01%	936

Other funds holding VYNE

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

LMR Partners's VYNE Position: Q4 2021 in Review

LMR Partners sold out of VYNE Therapeutics (VYNE) in Q4 2021, closing a stake of 1,098 shares — an estimated $27K sold.

LMR Partners first reported a position in VYNE in Q2 2021 and held it in 2 quarters. The position peaked at $69K in Q2 2021. 54 funds tracked by Wall St. Rank hold VYNE as of Q4 2021.

LMR Partners reported no remaining VYNE Therapeutics position as of Q4 2021 after selling out during the quarter.
LMR Partners sold 1,098 VYNE Therapeutics shares in Q4 2021, an estimated $27K.
LMR Partners first reported a position in VYNE Therapeutics in Q2 2021 and held it in 2 quarters.
LMR Partners's VYNE Therapeutics position peaked at $69K in Q2 2021.
54 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2021.

Based on LMR Partners's 13F filing for Q4 2021, filed 14 Feb 2022.